Ferguson Wellman Capital Management Upped Merck (MRK) Stake By $3.30 Million; Last Week StemCells, Inc. (STEM) Coverage

Among 4 analysts covering StemCells (NASDAQ:STEM), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. StemCells had 5 analyst reports since September 2, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of STEM in report on Wednesday, September 2 with “Buy” rating. H.C. Wainwright maintained StemCells, Inc. (NASDAQ:STEM) rating on Wednesday, December 30. H.C. Wainwright has “Buy” rating and $1.5 target. The stock of StemCells, Inc. (NASDAQ:STEM) earned “Hold” rating by Maxim Group on Tuesday, May 31. The stock has “Buy” rating by Rodman & Renshaw on Wednesday, April 20. The firm earned “Buy” rating on Tuesday, November 24 by H.C. Wainwright. See StemCells, Inc. (NASDAQ:STEM) latest ratings:

Ferguson Wellman Capital Management Inc increased Merck (MRK) stake by 4.33% reported in 2017Q3 SEC filing. Ferguson Wellman Capital Management Inc acquired 51,563 shares as Merck (MRK)’s stock declined 2.46%. The Ferguson Wellman Capital Management Inc holds 1.24 million shares with $79.62 million value, up from 1.19 million last quarter. Merck now has $166.85B valuation. The stock decreased 0.07% or $0.04 during the last trading session, reaching $61.24. About 1.37 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since January 22, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

It closed at $11.52 lastly. It is down 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Ferguson Wellman Capital Management Inc decreased Altria Group (NYSE:MO) stake by 47,632 shares to 318,923 valued at $20.23 million in 2017Q3. It also reduced Unitedhealth Group (NYSE:UNH) stake by 2,994 shares and now owns 177,822 shares. Tjx Companies (NYSE:TJX) was reduced too.

Among 23 analysts covering Merck & Co. Inc. (NYSE:MRK), 16 have Buy rating, 0 Sell and 7 Hold. Therefore 70% are positive. Merck & Co. Inc. has $7400 highest and $50 lowest target. $66.44’s average target is 8.49% above currents $61.24 stock price. Merck & Co. Inc. had 73 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Merck & Co., Inc. (NYSE:MRK) has “Overweight” rating given on Friday, September 9 by Barclays Capital. As per Friday, August 19, the company rating was maintained by UBS. The firm has “Buy” rating by Piper Jaffray given on Thursday, October 26. Piper Jaffray maintained the stock with “Buy” rating in Friday, July 28 report. The rating was upgraded by Piper Jaffray to “Overweight” on Thursday, January 12. The stock has “Neutral” rating by Bank of America on Wednesday, January 27. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Thursday, January 12 by Guggenheim. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Market Perform” rating by BMO Capital Markets on Monday, July 18. The stock of Merck & Co., Inc. (NYSE:MRK) has “Sell” rating given on Monday, July 17 by Jefferies. The stock has “Hold” rating by Jefferies on Tuesday, October 31.